Neurology
Huntington’s Gets Another Chance at Proof
ASCO 2026 showed how comprehensive genomic solutions are moving from research support to the practical backbone of cancer detection, profiling, monitoring and treatment matching.
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.